Small molecule inhibitor of Igf2bp1 represses Kras and a pro-oncogenic phenotype in cancer cells

References

• Degrauwe N, Suva ML, Janiszewska M, et al. IMPs: an RNA-binding protein family that provides a link between stem cell maintenance in normal development and cancer. Genes Dev. 2016;30:2459–2474.
   PubMed Web of Science ®Google Scholar
• Bell JL, Wachter K, Muhleck B, et al. Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression? Cell Mol Life Sci. 2013;70:2657–2675.
   PubMed Web of Science ®Google Scholar
• Ghoshal A, Rodrigues LC, Gowda CP, et al. Extracellular vesicle-dependent effect of RNA-binding protein IGF2BP1 on melanoma metastasis. Oncogene. 2019;38:4182–4196.
   PubMed Web of Science ®Google Scholar
• Gu L, Shigemasa K, Ohama K. Increased expression of IGF II mRNA-binding protein 1 mRNA is associated with an advanced clinical stage and poor prognosis in patients with ovarian cancer. Int J Oncol. 2004;24:671–678.
   PubMed Web of Science ®Google Scholar
• Hammerle M, Gutschner T, Uckelmann H, et al. Posttranscriptional destabilization of the liver-specific long noncoding RNA HULC by the IGF2 mRNA-binding protein 1 (IGF2BP1). Hepatology. 2013;58:1703–1712.
   PubMed Web of Science ®Google Scholar
• Ioannidis P, Kottaridi C, Dimitriadis E, et al. Expression of the RNA-binding protein CRD-BP in brain and non-small cell lung tumors. Cancer Lett. 2004;209:245–250.
   PubMed Web of Science ®Google Scholar
• Kato T, Hayama S, Yamabuki T, et al. Increased expression of insulin-like growth factor-II messenger RNA-binding protein 1 is associated with tumor progression in patients with lung cancer. Clin Cancer Res. 2007;13:434–442.
   PubMed Web of Science ®Google Scholar
• Kim T, Havighurst T, Kim K, et al. Targeting insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) in metastatic melanoma to increase efficacy of BRAF(V600E) inhibitors. Mol Carcinog. 2018b;57:678–683.
   PubMed Web of Science ®Google Scholar
• Kobel M, Weidensdorfer D, Reinke C, et al. Expression of the RNA-binding protein IMP1 correlates with poor prognosis in ovarian carcinoma. Oncogene. 2007;26:7584–7589.
   PubMed Web of Science ®Google Scholar
• Mongroo PS, Noubissi FK, Cuatrecasas M, et al. IMP-1 displays cross-talk with K-Ras and modulates colon cancer cell survival through the novel proapoptotic protein CYFIP2. Cancer Res. 2011;71:2172–2182.
   PubMed Web of Science ®Google Scholar
• Rosenfeld YB, Krumbein M, Yeffet A, et al. VICKZ1 enhances tumor progression and metastasis in lung adenocarcinomas in mice. Oncogene. 2019;38:4169–4181.
   PubMed Web of Science ®Google Scholar
• Vainer G, Vainer-Mossel E, Pikarsky A, et al. A role for VICKZ proteins in the progression of colorectal carcinomas: regulating lamellipodia formation. J Pathol. 2008;215:445–456.
   PubMed Web of Science ®Google Scholar
• Yaniv K, Yisraeli JK. The involvement of a conserved family of RNA binding proteins in embryonic development and carcinogenesis. Gene. 2002;287:49–54.
   PubMed Web of Science ®Google Scholar
• Kim HY, Ha Thi HT, Hong S. IMP2 and IMP3 cooperate to promote the metastasis of triple-negative breast cancer through destabilization of progesterone receptor. Cancer Lett. 2018a;415:30–39.
   PubMed Web of Science ®Google Scholar
• Craig EA, Spiegelman VS. Inhibition of coding region determinant binding protein sensitizes melanoma cells to chemotherapeutic agents. Pigment Cell Melanoma Res. 2012;25:83–87.
   PubMed Web of Science ®Google Scholar
• Glass M, Misiak D, Bley N, et al. IGF2BP1, a conserved regulator of RNA turnover in cancer. Front Mol Biosci. 2021;8: p. 632219.
   PubMed Web of Science ®Google Scholar
• Thein KZ, Biter AB, Hong DS. Therapeutics targeting mutant KRAS. Annu Rev Med. 2020. DOI:10.1146/annurev-med-080819-033145
   PubMed Web of Science ®Google Scholar
• Mackedenski S, Wang C, Li WM, et al. Characterizing the interaction between insulin-like growth factor 2 mRNA-binding protein 1 (IMP1) and KRAS expression. Biochem J. 2018;475:2749–2767.
   PubMed Web of Science ®Google Scholar
• Wu P. Inhibition of RNA-binding proteins with small molecules. Nat Rev Chem. 2020;4:441–458.
   PubMed Web of Science ®Google Scholar
• Maita H, Tomita K, Ariga H. A split luciferase-based reporter for detection of a cellular macromolecular complex. Anal Biochem. 2014;452:1–9.
   PubMed Web of Science ®Google Scholar
• Dagil R, Ball NJ, Ogrodowicz RW, et al. IMP1 KH1 and KH2 domains create a structural platform with unique RNA recognition and re-modelling properties. Nucleic Acids Res. 2019;47:4334–4348.
   PubMed Web of Science ®Google Scholar
• Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680–685.
   PubMed Web of Science ®Google Scholar
• Wilkins MR, Gasteiger E, Bairoch A, et al. Protein identification and analysis tools in the ExPASy server. Methods Mol Biol. 1999;112:531–552.
   PubMedGoogle Scholar
• Sommer G, Fedarovich A, Kota V, et al. Applying a high-throughput fluorescence polarization assay for the discovery of chemical probes blocking La: rNAinteractions in vitro and in cells. PLoS One. 2017;12: p. e0173246.
   PubMed Web of Science ®Google Scholar
• Cavanagh J, Skelton N, Fairbrother W, et al. Protein NMR Spectroscopy. London: Elsevier; 2006.
   Google Scholar
• Delaglio F, Grzesiek S, Vuister GW, et al. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J Biomol NMR. 1995;6:277–293.
   PubMed Web of Science ®Google Scholar
• Vranken WF, Boucher W, Stevens TJ, et al. The CCPN data model for NMR spectroscopy: development of a software pipeline. Proteins. 2005;59:687–696.
   PubMed Web of Science ®Google Scholar
• Patel VL, Mitra S, Harris R, et al. Spatial arrangement of an RNA zipcode identifies mRNAs under post-transcriptional control. Genes Dev. 2012;26:43–53.
   PubMed Web of Science ®Google Scholar
• Notredame C, Higgins DG, Heringa J. T-Coffee: a novel method for fast and accurate multiple sequence alignment. J Mol Biol. 2000;302:205–217.
   PubMed Web of Science ®Google Scholar
• Waterhouse AM, Procter JB, Martin DM, et al. Jalview Version 2–a multiple sequence alignment editor and analysis workbench. Bioinformatics. 2009;25:1189–1191.
   PubMed Web of Science ®Google Scholar
• Holm L. DALI and the persistence of protein shape. Protein Sci. 2020;29:128–140.
   PubMed Web of Science ®Google Scholar
• Chao JA, Patskovsky Y, Patel V, et al. ZBP1 recognition of beta-actin zipcode induces RNA looping. Genes Dev. 2010;24:148–158.
   PubMed Web of Science ®Google Scholar
• Nicastro G, Candel AM, Uhl M, et al. Mechanism of beta-actin mRNA Recognition by ZBP1. Cell Rep. 2017;18:1187–1199.
   PubMed Web of Science ®Google Scholar
• Bailey MH, Tokheim C, Porta-Pardo E, et al. Comprehensive characterization of cancer driver genes and mutations. Cell. 2018;173(371–385): p. e318.
   Google Scholar
• Moerke NJ. Fluorescence polarization (FP) assays for monitoring peptide-protein or nucleic acid-protein binding. Curr Protoc Chem Biol. 2009;1:1–15.
   PubMedGoogle Scholar
• Maizels Y, Oberman F, Miloslavski R, et al. Localization of cofilin mRNA to the leading edge of migrating cells promotes directed cell migration. J Cell Sci. 2015;128:1922–1933.
   PubMed Web of Science ®Google Scholar
• Nielsen J, Kristensen MA, Willemoes M, et al. Sequential dimerization of human zipcode-binding protein IMP1 on RNA: a cooperative mechanism providing RNP stability. Nucleic Acids Res. 2004;32:4368–4376.
   PubMed Web of Science ®Google Scholar
• Seidel SA, Dijkman PM, Lea WA, et al. Microscale thermophoresis quantifies biomolecular interactions under previously challenging conditions. Methods. 2013;59:301–315.
   PubMed Web of Science ®Google Scholar
• Farina KL, Huttelmaier S, Musunuru K, et al. Two ZBP1 KH domains facilitate beta-actin mRNA localization, granule formation, and cytoskeletal attachment. J Cell Biol. 2003;160:77–87.
   PubMed Web of Science ®Google Scholar
• Nicastro G, Taylor IA, Ramos A. KH-RNA interactions: back in the groove. Curr Opin Struct Biol. 2015;30:63–70.
   PubMed Web of Science ®Google Scholar
• Noubissi FK, Elcheva I, Bhatia N, et al. CRD-BP mediates stabilization of betaTrCP1 and c-myc mRNA in response to beta-catenin signalling. Nature. 2006;441:898–901.
   PubMed Web of Science ®Google Scholar
• Lavoie H, Gagnon J, Therrien M. ERK signalling: a master regulator of cell behaviour, life and fate. Nat Rev Mol Cell Biol. 2020;21:607–632.
   PubMed Web of Science ®Google Scholar
• Tang YN, Ding WQ, Guo XJ, et al. Epigenetic regulation of Smad2 and Smad3 by profilin-2 promotes lung cancer growth and metastasis. Nat Commun. 2015;6: p. 8230.
   PubMed Web of Science ®Google Scholar
• Muller S, Bley N, Busch B, et al. The oncofetal RNA-binding protein IGF2BP1 is a druggable, post-transcriptional super-enhancer of E2F-driven gene expression in cancer. Nucleic Acids Res. 2020;48:8576–8590.
   PubMed Web of Science ®Google Scholar
• Hamilton KE, Noubissi FK, Katti PS, et al. IMP1 promotes tumor growth, dissemination and a tumor-initiating cell phenotype in colorectal cancer cell xenografts. Carcinogenesis. 2013;34:2647–2654.
   PubMed Web of Science ®Google Scholar
• Muller S, Bley N, Glass M, et al. IGF2BP1 enhances an aggressive tumor cell phenotype by impairing miRNA-directed downregulation of oncogenic factors. Nucleic Acids Res. 2018;46:6285–6303.
   PubMed Web of Science ®Google Scholar
• Boyerinas B, Park SM, Murmann AE, et al. Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1. Int J Cancer. 2012;130:1787–1797.
   PubMed Web of Science ®Google Scholar
• Chen CL, Tsukamoto H, Liu JC, et al. Reciprocal regulation by TLR4 and TGF-beta in tumor-initiating stem-like cells. J Clin Invest. 2013;123:2832–2849.
   PubMed Web of Science ®Google Scholar
• Faye MD, Beug ST, Graber TE, et al. IGF2BP1 controls cell death and drug resistance in rhabdomyosarcomas by regulating translation of cIAP1. Oncogene. 2015;34:1532–1541.
   PubMed Web of Science ®Google Scholar
• Karras P, Riveiro-Falkenbach E, Canon E, et al. p62/SQSTM1 fuels melanoma progression by opposing mRNA decay of a selective set of pro-metastatic factors. Cancer Cell. 2019;35:46–63 e10.
   PubMed Web of Science ®Google Scholar
• Qin X, Sun L, Wang J. Restoration of microRNA-708 sensitizes ovarian cancer cells to cisplatin via IGF2BP1/Akt pathway. Cell Biol Int. 2017;41:1110–1118.
   PubMed Web of Science ®Google Scholar
• Oberman F, Rand K, Maizels Y, et al. VICKZ proteins mediate cell migration via their RNA binding activity. RNA. 2007;13:1558–1569.
   PubMed Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46:3–26.
   PubMed Web of Science ®Google Scholar
• Muller S, Glass M, Singh AK, et al. IGF2BP1 promotes SRF-dependent transcription in cancer in a m6A- and miRNA-dependent manner. Nucleic Acids Res. 2019;47:375–390.
   PubMed Web of Science ®Google Scholar
• Xu H, Niu M, Yuan X, et al. CD44 as a tumor biomarker and therapeutic target. Exp Hematol Oncol. 2020;9: p. 36.
   PubMed Web of Science ®Google Scholar
• Vikesaa J, Hansen TV, Jonson L, et al. RNA-binding IMPs promote cell adhesion and invadopodia formation. Embo J. 2006;25:1456–1468.
   PubMed Web of Science ®Google Scholar
• Beaulieu ME, Castillo F, Soucek L. Structural and biophysical insights into the function of the intrinsically disordered myc oncoprotein. Cells. 2020;9: p. 1038.
   PubMed Web of Science ®Google Scholar
• Doyle GA, Betz NA, Leeds PF, et al. The c-myc coding region determinant-binding protein: a member of a family of KH domain RNA-binding proteins. Nucleic Acids Res. 1998;26:5036–5044.
   PubMed Web of Science ®Google Scholar
• Tessier CR, Doyle GA, Clark BA, et al. Mammary tumor induction in transgenic mice expressing protein. Cancer Res. 2004;64:209–214.
   PubMed Web of Science ®Google Scholar
• Mahapatra L, Andruska N, Mao C, et al. A novel IMP1 inhibitor, BTYNB, targets c-Myc and inhibits melanoma and ovarian cancer cell proliferation. Transl Oncol. 2017;10:818–827.
   PubMed Web of Science ®Google Scholar
• JnBaptiste CK, Gurtan AM, Thai KK, et al. Dicer loss and recovery induce an oncogenic switch driven by transcriptional activation of the oncofetal Imp1-3 family. Genes Dev. 2017;31:674–687.
   PubMed Web of Science ®Google Scholar
• Huang H, Weng H, Sun W, et al. Recognition of RNA N(6)-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat Cell Biol. 2018;20:285–295.
   PubMed Web of Science ®Google Scholar
• Uddin MB, Wang Z, Yang C. The m(6)A RNA methylation regulates oncogenic signaling pathways driving cell malignant transformation and carcinogenesis. Mol Cancer. 2021;20: p. 61.
   PubMed Web of Science ®Google Scholar
• Li B, Zhu L, Lu C, et al. circNDUFB2 inhibits non-small cell lung cancer progression via destabilizing IGF2BPs and activating anti-tumor immunity. Nat Commun. 2021;12: p. 295.
   PubMed Web of Science ®Google Scholar